PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Clinical trials for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) explained in plain language.
Never miss a new study
Get alerted when new PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) trials appear
Sign up with your email to follow new studies for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare overgrowth disorder: drug trial targets root cause
Disease control Recruiting nowThis study tests a daily oral drug called alpelisib in children and adults with PROS, a rare condition causing abnormal tissue growth. The goal is to see if the drug can shrink overgrowths and improve symptoms. Participants must be at least 2 years old and have active, worsening …
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
New drug offers hope for rare overgrowth disorders
Disease control Recruiting nowThis study tests a drug called CYH33 in people with rare conditions that cause abnormal tissue growth and blood vessel problems. The goal is to see if the drug can safely shrink overgrown tissue and control the disease. About 141 adults and teens aged 12 and older will take part.
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE1, PHASE2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
New drug aims to shrink overgrown tissue in rare genetic disorder
Disease control Recruiting nowThis study tests a new drug, RLY-2608, in adults and children with rare conditions that cause abnormal overgrowth of body parts (like limbs or organs) due to a PIK3CA gene mutation. The drug targets only the mutated protein to try to reduce the size of overgrown tissue and improv…
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
Last-Resort access: alpelisib opens for patients with no other options
Disease control AVAILABLEThis program provides access to the drug alpelisib (BYL719) for patients with serious conditions like PIK3CA-related overgrowth spectrum (PROS) or breast cancer who have no other treatment options and cannot join a clinical trial. It is not a standard study but a managed access p…
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 20, 2026 11:54 UTC